Health
Researchers develop promising new drug candidates to treat ALS – Drug Target Review
Scientists have shown that a Selenium-based drug-molecule called ebselen and other novel compounds can delay ALS onset in mouse models.
Posted: 2 September 2020 | Victoria Rees (Drug Target Review) | No comments yet
Scientists have shown that a Selenium-based drug-molecule called ebselen and other novel compounds can delay ALS onset in mouse models.
Scientists report that they have taken a significant step forward in the search to find effective new drugs for the treatment of Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease.
Researchers from the University of Liverpool, UK, and University of Nagoya, Ja…
-
Business14 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts